Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Leveraging phased variants for personalized minimal residual disease detection in localized non-small cell lung cancer.

Phased variants had a lower background rate than SNVs, including duplex SNVs (1.2e-6 vs 3.8e-5 and 1.0e-5). PhasED-Seq detected all 5 SNV-positive samples and 5 additional samples at tumor fractions as low as 0.000094%. In one patient with stage III adenocarcinoma, PhasED-Seq detected MRD in three on-treatment samples that were undetectable by SNVs, including a sample 8 months before progression.

ASCO Annual Meeting 2021